首页> 外文期刊>International Journal of Biomedical and Advance Research >Study of serum ferritin, serum uric acid and plasma malondialdehyde (MDA) levels in non-alcoholic fatty liver disease
【24h】

Study of serum ferritin, serum uric acid and plasma malondialdehyde (MDA) levels in non-alcoholic fatty liver disease

机译:非酒精性脂肪肝患者血清铁蛋白,血清尿酸和血浆丙二醛(MDA)水平的研究

获取原文
           

摘要

Background: Non-alcoholic fatty liver disease (NAFLD) is one of most important cause of fatty liver that may lead to end-stage liver disease. Various studies have reported that serum ferritin, serum uric acid and plasma malondialdehyde (MDA) levels are related to the development of NAFLD. Diabetes and obesity are the major risk factors which are associated with NAFLD. The aim of this study was assessment of serum ferritin, serum uric acid and plasma MDA levels in NAFLD patients with diabetes and with obesity. Materials and Methods: In the present study, total (n = 230) subjects were recruited for the study and divided in three groups. Group I; (n = 79) diagnosed cases of non-alcoholic fatty liver disease with diabetes, group II; (n = 91) diagnosed cases of non-alcoholic fatty liver disease with obesity patients and group III included (n = 80) healthy control subjects. Serum ferritin was measured by ELISA method. Estimation of serum uric acid was done by uricase peroxidase colorimetric method. Plasma MDA was estimated by spectrophotometric method. Results: The present study shown that serum ferritin, serum uric acid and plasma MDA levels were significantly increased (p<0.001) in NAFLD with diabetes mellitus patients (533.42202.93, 14.291.87, 7.753.35, respectively) as compared with healthy controls (126.3072.12, 5.191.72, 2.790.52, respectively), and also significantly increased (p < 0.001) in NAFLD with obesity patients (500.87185.80, 12.082.81, 7.433.05, respectively) when they compared with healthy controls (126.3072.12, 5.191. 2.790.52, respectively). Conclusion: Serum ferritin, uric acid and MDA are associated with the increasing risk for non-alcoholic fatty liver disease.
机译:背景:非酒精性脂肪肝疾病(NAFLD)是脂肪肝的最重要原因之一,可能导致终末期肝病。各种研究报道,血清铁蛋白,血清尿酸和血浆丙二醛(MDA)水平与NAFLD的发生有关。糖尿病和肥胖是与NAFLD相关的主要危险因素。这项研究的目的是评估NAFLD糖尿病和肥胖患者的血清铁蛋白,血清尿酸和血浆MDA水平。材料和方法:在本研究中,共招募了230名受试者,并将其分为三组。第一组; (n = 79)诊断为糖尿病的非酒精性脂肪肝疾病病例,第二组; (n = 91)患有肥胖症患者的非酒精性脂肪肝疾病的诊断病例​​,III组包括(n = 80)健康对照组。通过ELISA法测定血清铁蛋白。用尿酸酶过氧化物酶比色法估算血清尿酸。通过分光光度法估算血浆MDA。结果:本研究表明,与健康人相比,糖尿病合并NAFLD患者的血清铁蛋白,血清尿酸和血浆MDA水平显着升高(p <0.001)(分别为533.42202.93、14.291.87、7.753.35)。与肥胖患者相比(分别为500.87185.80、12.082.81、7.433.05)和肥胖患者(分别为126.3072.12、5.191.72、2.7905.52)和NAFLD显着增加(p <0.001)健康对照(分别为126.3072.12、5.191和2.790.52)。结论:血清铁蛋白,尿酸和丙二醛与非酒精性脂肪肝的风险增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号